Sugg and Harris and their respective coworkers were the first to study extensively the immunologic properties of a strain of pneumococcus closely related to, but not identical with, typical strains of Type III pneumococci (1, 2). The " Thomas " strain of these workers now can be classified definitely as a Type VIII pneumococcus, according to the classification of Cooper et al. (3). Both the Thomas strain and the Type VIII strains were shown, by these respective investigators, to produce in certain animal species antibodies of high titer against typical strains of Type III pneumococci. The titers were sometimes higher than the notoriously low homologous antibody titers obtainable by the injection of typical Type III strains. The reciprocal serological relationships between typical Type III strains and the related Type VIII strains were demonstrated with regard to passive protection in mice, agglutination, and precipitation. Antibody relationships similar to those described in the sera of lower animals were shown, by Finland and Winkler (4), to occur also in the sera of certain human subjects during convalescence from pneumonia due to these types. With regard to " natural antibodies," as measured by the pneumococcidal power of the whole defibrinated blood or the protection afforded mice by the serum of normal human subjects, Finland and Sutliff found no such reciprocal relationship (5).
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The specific carbohydrate from Pneumococcus Type VIII was recently isolated and its properties described by Brown (6) . She found marked cross-precipitation between this carbohydrate and that of the Type III pneumococcus. In view of this finding and because of the poor antibody response of human subjects to injections of the Type III polysaccharide (7) , it seemed of interest to study the effect of injections of the Type VIII carbohydrate. This paper deals with the antibody responses to such injections and a comparison of them with the results of similar injections of different preparations of the specific Type III polysaccharide. Variations in the antibody response due to differences in dosage and in the route of injection are dealt with in a separate communication (8) . EXPERIMENTAL 
Subjects, materials and methods
The Type VIII carbohydrate was obtained from Dr. Rachel Brown and was, in most respects, similar to the preparation which she described (6) . Her The results are summarized in Table II . In general, inconstant and low-grade responses were secured. They were similar to those previously obtained with the smaller doses given intracutaneously (7) and somewhat less marked than those observed to develop in patients recovering from pneumonia due to the same type of pneumococcus (4) . Table II . Only 1 of the subjects (F. S.) injected with the Type VIII material showed an appreciable development of antibodies for the Type III organism. Other subjects, as described in the paper that follows (8), were encountered whose sera showed Type III antibodies in low titer following the injection of the Type VIII material in different amounts or by routes other than the subcutaneous one.
The Type III preparations used were all similar in their antigenicity as regards both the homologous and the related type of antibody. Antibodies of significant titer against Type VIII following injections of Type III polysaccharide were infrequent. Low titers of such antibodies, however, were demonstrated in almost half of the subjects who received Type III materials.
The findings described indicate that the common antigen of the Types III and VIII pneumococci is retained, at least in part, in these highly purified fractions. Less of it is retained in the Type VIII than in the Type III materials. In either case, however, the antibody response to the related type was less frequent than that following injections of the intact organisms in lower animals (1, 2, 3) , or than that found in patients recovering from pneumonia due to these types (4).
Development of antibodies againist heterologous
and unrelated pneumococcus types The development of antibodies for heterologous types of pneumococci has been reported to follow injections of Type I and II pneumococcus fractions in lower animals (13) and in human beings (14) . In the present investigation, in addition to tests for antibodies against the homologous and the related types of organisms (Type III and Type VIII), similar tests were carried out on the sera of each subject with either Type I These findings indicate that a species antigen may be present in the pneumococcus but that it is largely lost in the process of preparation of the carbohydrate fractions (cf. 15). In the case of some of the Type III preparations, the data suggest that sufficient of this species antigen was retained to give rise to Type I or Type II antibodies in measurable amounts in an occasional subject. SUMMARY 1. High titers of antibodies against the homologous type were demonstrated regularly in human subjects following the subcutaneous injection of 1.0 mgm. of a highly purified, type-specific carbohydrate of Pneumococcus Type VIII.
2. Various preparations of the Type III pneumococcus polysaccharide, given in the same manner, produced antibodies for the homologous type with less regularity and in lower titers.
3. Occasional subjects injected with Type III or with the related Type VIII pneumococcus carbohydrate developed antibodies against pneumococci of the heterologous but related type. Such cross-immunity, however, was less frequent and of a lower grade than that encountered either in animals immunized with the whole organism or in human patients recovering from pneumonia due to these types of pneumococcus.
